| Quantity | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 1 mg, 5 mg | 100 µ, g, 500 µ, g, 1 mg | 5 mg, 10 mg, 25 mg |
| Description | WYRGRL, a collagen II-targeting peptide, can bind to collagen II α1. WYRGRL is a short cartilage-targeting peptide sequence. WYRGRL leads to about 72-fold increase of cartilage-targeting efficiency for the peptide-functionalized nanoplatform in vivo[1][2] | Alkaline phosphatase, Bovine intestine (Apase) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase can be used in molecular biology and enzyme-free analysis. Inhibition of tissue nonspecific alkaline phosphatase can block Alkaline phosphatase, Bovine intestine (Apase) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase can be used in molecular biology and enzyme-free analysis. Inhibition of tissue nonspecific alkaline phosphatase can block intracellular lipid accumulation[1][2]... Read More | Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ[1][2][3][4]... Read More | Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities[1][2] | Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3]... Read More |